CurrentAetnaPolicy 0229

Iontophoresis

Coverage and medical necessity criteria for iontophoresis procedures and sweat testing by pilocarpine iontophoresis; affects Aetna members and providers requesting coverage for iontophoresis services.

Policy Summary

PayerAetna

PolicyIontophoresis

Policy CodePolicy 0229

Change TypeNo material changes noted

Effective DateN/A

Next Review DateFeb 22, 2024

Key ActionObtain and document prior therapy trials and clinical justification (e.g., failed topical antiperspirants and oral therapy) before requesting iontophoresis for primary focal hyperhidrosis.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1Covered CPT codes (if criteria met)

89230Sweat test CPT

>=60CF sweat chloride threshold

MultipleExperimental indications listed

Low/Very LowEvidence quality

85%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Hyperhidrosis response rate

Coverage and Medical Necessity Criteria

Evidence summaries / clinical findings

Top-level evidence summaries and clinical findings related to iontophoresis across indications.

Evidence is limited and variable in quality across indications; many studies are small, short-term, or at high risk of bias.

Systematic reviews and technology assessments (e.g., BCBSA TEC 2003) found insufficient evidence that iontophoretic delivery of NSAIDs or corticosteroids for musculoskeletal inflammatory disorders provides benefits beyond placebo or alternative delivery routes.

For musculoskeletal conditions (adhesive capsulitis, rotator cuff disease, tendinopathy, lateral epicondylitis, neck pain), available RCTs and reviews report inconsistent or very low–quality evidence; pooled data do not demonstrate consistent intermediate- to long-term clinical benefit for iontophoresis compared with placebo or observation.

Electrotherapy modalities reviews (Cochrane and other systematic reviews) indicate very low–low quality evidence that modulated galvanic current, iontophoresis, and electric muscle stimulation are not more effective than placebo for some outcomes; further high-quality trials are needed.

For carpal tunnel syndrome, evidence from small RCTs and systematic reviews is mixed: some short- to mid-term benefits reported for certain electrophysical modalities in specific comparisons, but DEX iontophoresis trials did not show clear objective benefit and overall long-term RCT data are lacking.

Iontophoretic fentanyl transdermal systems have moderate-quality evidence from randomized trials showing efficacy as an alternative to IV patient-controlled analgesia (PCA) for acute post-operative pain, with favorable patient-reported convenience and comparable analgesia in large trials.

Primary focal hyperhidrosis (palmar/plantar): limited randomized data and reviews report symptom relief in a substantial proportion of patients (approximately 85% in some reports) with iontophoresis; long-term data are limited.

Peyronie’s disease: systematic reviews and pooled analyses report that iontophoresis (including verapamil) and topical/combination therapies did not demonstrate consistent improvements in curvature, plaque size, or function; evidence insufficient to support verapamil iontophoresis.

Transepithelial corneal collagen cross-linking delivered by iontophoresis (I-CXL) for keratoconus: RCTs and systematic reviews show limited, very low–quality evidence. Some trials report modest improvements in keratometry and visual acuity at 12 months, but I-CXL appears less effective than conventional (epithelium-off) CXL in comparative studies and has higher failure rates; adverse events are generally transient.

Plantar/heel pain and calcific tendinitis: small uncontrolled studies and limited trials (e.g., acetic acid iontophoresis) report symptomatic improvement, but evidence quality is low and findings require validation in well-designed RCTs.

Palmoplantar psoriasis: small pilot RCTs report mixed results for methotrexate iontophoresis versus topical corticosteroid, with safety concerns (burn injuries) reported in some iontophoresis groups; evidence is insufficient.

Induction of bowel evacuation in spinal cord injury: phase I, proof-of-principle studies suggest transdermal neostigmine/glycopyrrolate by iontophoresis can induce bowel movements in some responders with fewer systemic side effects than IV administration, but findings require validation in larger controlled trials.

Tinnitus (lidocaine iontophoresis): systematic review found heterogeneous, low-quality studies with widely varying benefit (4%–62%); overall evidence rated weak and inconclusive—electrical stimulation effects cannot be excluded.

Across many indications, common limitations include small sample sizes, short follow-up, heterogeneity of treatment parameters, lack of blinding, and inconsistent outcome measures, which limit confidence in effect estimates and generalizability.

Coding and Diagnostic Thresholds

Covered CPT Codes (if selection criteria met)CPTCovered

97033

Application of a modality to one or more areas; iontophoresis, each 15 minutes.

Sweat Test CPT Code (covered if selection criteria met)CPTCovered

89230

Sweat collection by iontophoresis.

HCPCS/J-codes Not Covered when administered by iontophoresisHCPCSNot Covered

J3285	Injection, treprostinil
J7686	Treprostinil, inhalation solution, FDA-approved final product

ICD-10 Codes Covered if selection criteria are met / referencedICD-10

G89.12	Acute post-thoracotomy pain
G89.18	Other acute post-operative pain
L74.510 - L74.519	Primary focal hyperhidrosis
L74.52	Secondary focal hyperhidrosis
R61	Generalized hyperhidrosis
E84.0 - E84.9	Cystic fibrosis

ICD-10 Codes Not Covered for listed indications (examples)ICD-10Not Covered

B00.50 - B00.59

Herpesviral ocular disease

No codes provided in this excerptmixed

No codes listed

No codes listed in this excerptmixed

No codes listed

inv-23: Sweat chloride diagnostic threshold for cystic fibrosis — key diagnostic threshold value.

Diagnostic threshold> 60 mEq/L chloride in sweat (confirms cystic fibrosis in patients with suggestive clinical picture or positive family history)

Test methodPilocarpine iontophoresis stimulates localized sweating pharmacologically and measures sweat sodium and chloride

Clinical contextUsed to confirm diagnosis of cystic fibrosis when clinical suspicion or family history present

inv-24: CXL progression indicator — Increase in maximum keratometry >= 1.5 diopters at 12 months.

Progression indicator (CXL trials)

Prior Authorization, Documentation, and Provider Requirements

Billing Rule

Billing and drug-code restrictions

Drug codes not covered when delivered by iontophoresis — Certain drug and HCPCS/J-codes are noted as not covered when administered via iontophoresis. Examples include J3285 (treprostinil injection) and J7686 (treprostinil inhalation solution) when billed based on iontophoretic administration; other investigational formulations (e.g., gold nanoparticles, nanoethosomal piroxicam, acetic acid, ascorbic acid) have no specific code and are considered not covered for the experimental indications listed in the policy.

Affected codes: J3285, J7686
Investigational/no specific code examples: gold nanoparticles with iontophoresis, nanoethosomal piroxicam, acetic acid iontophoresis, ascorbic acid iontophoresis

Denial Risk

Procedural/coding denials

Background and Mechanism

Iontophoresis uses continuous direct electrical current to enhance transdermal delivery of ionizable drugs. Pilocarpine iontophoresis is the standard sweat-stimulating technique used to collect sweat for chloride measurement in the diagnostic evaluation of cystic fibrosis; a sweat chloride concentration >60 mEq/L is diagnostic in the appropriate clinical context.

Definitions and Key Terms

inv-53: Sweat test by pilocarpine iontophoresis — definition of the laboratory test used to diagnose cystic fibrosis.

DefinitionLaboratory sweat test that pharmacologically stimulates localized sweating using pilocarpine delivered by iontophoresis

MeasurementsCollected sweat volume with measurement of sodium and chloride concentrations

Diagnostic usePractical and reliable laboratory test to confirm cystic fibrosis when interpreted with clinical picture or family history

inv-54: Primary focal hyperhidrosis — definition (axillae, palms, soles) and functional impact.

Anatomic sitesPrimary focal hyperhidrosis involves axillae, palms, or soles

Functional impact

Policy Summary

PayerAetna

PolicyIontophoresis

Policy CodePolicy 0229

Change TypeNo material changes noted

Effective DateN/A

Next Review DateFeb 22, 2024

Key ActionObtain and document prior therapy trials and clinical justification (e.g., failed topical antiperspirants and oral therapy) before requesting iontophoresis for primary focal hyperhidrosis.

SourceLink

On This Page

Increase in maximum keratometry >= 1.5 diopters at 12 months

Outcome timingPrimary progression outcome assessed at 12 months in RCTs

Source contextDefined as a primary indicator of keratoconus progression in Cochrane review of CXL

inv-25: Increase in maximum keratometry — >= 1.5 diopters (primary outcome at 12 months in CXL RCTs).

Keratometry change (primary outcome)>= 1.5 diopters increase in maximum keratometry (Kmax) at 12 months

Role in trialsUsed as a binary indicator of progression (increase >=1.5 D) in RCTs reviewed

Evidence quality noteCochrane reviewers judged available trials low/very low quality with imprecision and risk of bias

inv-26: Deterioration in UCVA — > 0.2 logMAR (primary outcome at 12 months in CXL RCTs).

UCVA deterioration (primary outcome)> 0.2 logMAR worsening in uncorrected visual acuity at 12 months

Outcome roleDeterioration in UCVA >0.2 logMAR used alongside Kmax increase as a primary progression endpoint

Trial limitationsTrials small and at high risk of bias; estimates imprecise

No explicit procedural or coding denial triggers specified — The policy does not define additional procedural or coding denial rules beyond the coverage and non-coverage code lists; providers should follow the CPT/HCPCS/ICD-10 listings in the policy and submit documentation that meets the medical necessity criteria.

Follow covered CPT codes (e.g., 97033, 89230) when selection criteria are met
Non-covered/experimental code examples are listed in the policy chunks

Prior Authorization

Prior authorization / denial criteria

No authorization or denial criteria provided in this excerpt — The policy sections included do not state explicit prior authorization requirements or operational denial criteria; when prior authorization is required by the payer or plan, providers must follow plan-specific authorization processes.

Check plan-level prior authorization rules for CPT 97033 and CPT 89230 where applicable
Policy history and additional resources do not list authorization workflows

Documentation Required

Clinical trial measurement notes

Clinical trial descriptions include objective measurements and patient questionnaires — The evidence summary and trial reports referenced in the policy describe objective outcome measures (e.g., sweat chloride concentration for cystic fibrosis diagnosis, keratometry and UCVA for keratoconus trials, pain scores and functional assessments in musculoskeletal studies) and use validated patient questionnaires in some trials.

Sweat test: pilocarpine iontophoresis with measured chloride concentration (>60 mEq/L confirms CF)
Keratoconus trials: maximum keratometry and UCVA at 12 months
Musculoskeletal trials: patient-reported pain measures and validated questionnaires

Step Therapy

Conservative-first approach for hyperhidrosis

Conservative-first approach (informational) — Topical antiperspirants (e.g., aluminum chloride) are typically tried before iontophoresis for primary focal hyperhidrosis; iontophoresis is considered when topical therapies and oral pharmacotherapy are ineffective or not tolerated.

Step sequence for hyperhidrosis: topical antiperspirants → oral pharmacotherapy (if used) → iontophoresis for intractable, disabling primary focal hyperhidrosis

Note

Iontophoresis for plantar fasciitis / heel pain (informational)

For plantar fasciitis/heel pain, iontophoresis protocols referenced in the literature are small-trial and not established as standard requirement — examples include a 0.4% dexamethasone protocol (6 sessions) and studies using acetic acid; these trials showed short-term or inconsistent benefit and are not listed as recommended standard care in the policy.

Small randomized trial: iontophoresis with 0.4% dexamethasone, 6 sessions over 2 weeks — moderate initial relief not maintained at 4 weeks
Other small studies: acetic acid iontophoresis results inconsistent and not included in summary recommendations

Step Therapy

Step therapy and trial requirements

No step therapy requirements described in these policy excerpts — Apart from the conservative-first note for hyperhidrosis (topical antiperspirants before iontophoresis), the policy chunks do not specify formal step-therapy protocols or mandatory trials beyond the stated medical necessity criteria.

Documented trials required where specified in medical necessity criteria (e.g., failure/intolerance of oral pharmacotherapy and topical aluminum chloride for hyperhidrosis)
No additional step-therapy rules provided in the policy excerpts

Note

Policy history and administrative dates

Policy includes review history and effective/next review dates — The policy history and administrative information are present in the source: effective date (04/22/1998), last review (04/26/2023), and next review (02/22/2024).

Effective date: 04/22/1998
Last review: 04/26/2023
Next review: 02/22/2024

Intractable, disabling excessive sweating causing significant disruption of professional and/or social life

Therapy contextConsidered for iontophoresis when unresponsive or intolerant to oral pharmacotherapy and topical antiperspirants

inv-55: Active vs passive transdermal delivery — definition and distinction.

Passive deliveryOptimizes formulation or vehicle to increase skin permeability but limited for molecules >500 Da

Active deliveryUses physical energy (iontophoresis, electroporation, ultrasound) to enhance penetration and deliver a wider range of molecular sizes

ImplicationActive methods generally superior for larger molecules and peptides/proteins compared with passive approaches

inv-56: Fentanyl iontophoretic transdermal system (ITS) — definition and clinical context.

DefinitionA system delivering fentanyl transdermally via iontophoresis (fentanyl ITS) for patient-controlled analgesia

Clinical contextEvaluated as an alternative to intravenous morphine PCA for acute post-operative pain in randomized trials

Patient experienceStudies reported favorable patient assessments for convenience and some subscales of satisfaction versus IV PCA

inv-57: Electrotherapy modalities — brief definition listing related modalities.

DefinitionElectrotherapy modalities encompass interventions using electrical or electromagnetic energy such as LLLT, PEMF, therapeutic ultrasound, TENS, iontophoresis, microcurrent electrical stimulation and diathermy

Clinical useApplied in musculoskeletal and soft-tissue disorders often studied alongside manual therapy or exercise

Evidence noteEvidence quality varies; some modalities show low-to-moderate short-term benefits in small trials

inv-58: Iontophoresis (in ophthalmology context) — definition and usage in transepithelial CXL and drug delivery.

Definition (ophthalmology)Iontophoresis is a method of trans-epithelial drug delivery used to perform transepithelial corneal collagen cross-linking (I-CXL) and to deliver agents to ocular tissue

Usage in CXLUsed in transepithelial (epithelium-on) CXL for progressive keratoconus, with reported improvements in UCVA and Kmax in preliminary studies

Clinical limitationsTrials are small and heterogeneous; long-term effectiveness compared to conventional C-CXL remains uncertain

inv-59: I-CXL — definition (iontophoresis-assisted transepithelial corneal collagen cross-linking).

DefinitionI-CXL: iontophoresis-assisted transepithelial corneal collagen cross-linking (transepithelial technique)

TechniquePerforms CXL without removing the epithelium using iontophoresis to enhance riboflavin penetration

Clinical comparisonSome studies show higher failure rates for I-CXL versus conventional epithelium-off C-CXL

inv-60: C-CXL — definition (conventional epithelium-off corneal collagen cross-linking).

DefinitionC-CXL: conventional corneal collagen cross-linking using an epithelium-off technique

Clinical performanceReported to have greater efficacy and lower failure rates compared with iontophoresis-assisted transepithelial CXL in some studies

Observed outcomesC-CXL associated with more visible stromal demarcation line and lower I-CXL failure rate (e.g., 7.5% vs 20% at 2 years in one study)

inv-61: Iontophoresis — general definition and examples of agents delivered (dexamethasone, lidocaine, etc.).

General definitionIontophoresis: electrically-assisted transdermal delivery of ionizable medications using continuous direct current

Example agentsExamples of agents delivered include dexamethasone, lidocaine, acetic acid, verapamil, neostigmine/glycopyrrolate and others

Clinical contextsUsed across indications such as dermatologic conditions, hyperhidrosis, analgesia (fentanyl ITS), and investigational uses (e.g., Peyronie's disease, tinnitus)